Matches in Wikidata for { <http://www.wikidata.org/entity/Q60910566> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- Q60910566 description "article scientifique publié en 2019" @default.
- Q60910566 description "im Februar 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q60910566 description "wetenschappelijk artikel" @default.
- Q60910566 description "наукова стаття, опублікована в лютому 2019" @default.
- Q60910566 name "Potential efficacy and prognosis of silencing the CRLF2‑mediated AKT/mTOR pathway in pediatric acute B‑cell lymphoblastic leukemia" @default.
- Q60910566 name "Potential efficacy and prognosis of silencing the CRLF2‑mediated AKT/mTOR pathway in pediatric acute B‑cell lymphoblastic leukemia" @default.
- Q60910566 type Item @default.
- Q60910566 label "Potential efficacy and prognosis of silencing the CRLF2‑mediated AKT/mTOR pathway in pediatric acute B‑cell lymphoblastic leukemia" @default.
- Q60910566 label "Potential efficacy and prognosis of silencing the CRLF2‑mediated AKT/mTOR pathway in pediatric acute B‑cell lymphoblastic leukemia" @default.
- Q60910566 prefLabel "Potential efficacy and prognosis of silencing the CRLF2‑mediated AKT/mTOR pathway in pediatric acute B‑cell lymphoblastic leukemia" @default.
- Q60910566 prefLabel "Potential efficacy and prognosis of silencing the CRLF2‑mediated AKT/mTOR pathway in pediatric acute B‑cell lymphoblastic leukemia" @default.
- Q60910566 P1433 Q60910566-5DBFDECD-ADB8-490D-89FC-DF7DA3919CFE @default.
- Q60910566 P1476 Q60910566-32DC51CC-6802-4705-8369-5D92D365D00F @default.
- Q60910566 P2093 Q60910566-56C50F52-AF15-4638-9E50-58303EEFB211 @default.
- Q60910566 P2093 Q60910566-5862838F-F59E-47A1-95B5-0F4F9AC9B56B @default.
- Q60910566 P2093 Q60910566-E18D2EEB-3E8C-4D28-A1FD-92F7779DCE82 @default.
- Q60910566 P2860 Q60910566-02987D8B-4008-40A3-93F2-DEF417419D93 @default.
- Q60910566 P2860 Q60910566-171C1CC1-5C95-4E3C-A29E-88385A4E0187 @default.
- Q60910566 P2860 Q60910566-1C469F49-A9E0-45E9-961D-84D2576103F1 @default.
- Q60910566 P2860 Q60910566-23355BB0-FEFE-4116-88F3-E6B098674445 @default.
- Q60910566 P2860 Q60910566-250CE6E8-FB4B-4135-A8D5-46088448CB81 @default.
- Q60910566 P2860 Q60910566-56C605A1-BDE2-4986-AC71-073593095A36 @default.
- Q60910566 P2860 Q60910566-5D18C2CD-CF43-4348-9A2B-632D120E3738 @default.
- Q60910566 P2860 Q60910566-61D760FF-9620-45A5-B29F-6E3567A2A195 @default.
- Q60910566 P2860 Q60910566-676D9C54-D324-46F5-9C24-B5A55287F23C @default.
- Q60910566 P2860 Q60910566-6C4529B7-4158-4593-B5EE-F2F12872DE0B @default.
- Q60910566 P2860 Q60910566-AE5D9875-7595-4DF1-A7FF-5F2BA48DCD41 @default.
- Q60910566 P2860 Q60910566-BDF642D6-7143-4100-A3E4-4F0FA07F8017 @default.
- Q60910566 P2860 Q60910566-CA86998F-48DF-409E-AC8F-5E3336F774B1 @default.
- Q60910566 P2860 Q60910566-DDF7C0AA-3C4D-40BC-8F4F-E25B331571B2 @default.
- Q60910566 P2860 Q60910566-EA6A9FE4-898C-4A31-9605-7E697C07F5D7 @default.
- Q60910566 P2860 Q60910566-F605AA6E-F9D9-452A-B216-5FBA6EBC1A7E @default.
- Q60910566 P2860 Q60910566-F6BAB776-2998-4333-916F-3A3912E2A43E @default.
- Q60910566 P304 Q60910566-F5C980A0-1073-4A9E-90D4-A0C1FF5D2302 @default.
- Q60910566 P31 Q60910566-0A663A5D-1D8D-4AC5-A4EF-F0B56926ECDC @default.
- Q60910566 P356 Q60910566-9E3F36EE-0E56-4AD6-81C4-DF7911CF0C35 @default.
- Q60910566 P407 Q60910566-0FF77F02-C034-458F-8620-C02C5DC7E8F5 @default.
- Q60910566 P433 Q60910566-3C0D4864-8DF9-4613-8310-298C7C91A277 @default.
- Q60910566 P478 Q60910566-D876421A-7278-428F-A409-16D9F8CBB84C @default.
- Q60910566 P577 Q60910566-B196B94F-3424-4146-8F55-BF9CCB33A0B9 @default.
- Q60910566 P698 Q60910566-523BC1D3-E8A0-4F47-8352-2FD39A34229C @default.
- Q60910566 P921 Q60910566-3EDDD277-DD99-4A9B-AB71-2AE775AD598E @default.
- Q60910566 P921 Q60910566-F96A26F2-B8C2-4927-BC8E-FFF207DF3144 @default.
- Q60910566 P932 Q60910566-5144143B-8A37-4A27-92FC-BAC2FAF60AE4 @default.
- Q60910566 P356 OR.2018.6917 @default.
- Q60910566 P698 30535452 @default.
- Q60910566 P1433 Q7092098 @default.
- Q60910566 P1476 "Potential efficacy and prognosis of silencing the CRLF2‑mediated AKT/mTOR pathway in pediatric acute B‑cell lymphoblastic leukemia" @default.
- Q60910566 P2093 "Lingyun Lu" @default.
- Q60910566 P2093 "Min Jiang" @default.
- Q60910566 P2093 "Xueqin Zou" @default.
- Q60910566 P2860 Q33429079 @default.
- Q60910566 P2860 Q36141916 @default.
- Q60910566 P2860 Q36352535 @default.
- Q60910566 P2860 Q37102970 @default.
- Q60910566 P2860 Q37429718 @default.
- Q60910566 P2860 Q39119297 @default.
- Q60910566 P2860 Q39348485 @default.
- Q60910566 P2860 Q40275129 @default.
- Q60910566 P2860 Q40537705 @default.
- Q60910566 P2860 Q40607280 @default.
- Q60910566 P2860 Q40972778 @default.
- Q60910566 P2860 Q44018556 @default.
- Q60910566 P2860 Q46208779 @default.
- Q60910566 P2860 Q47164848 @default.
- Q60910566 P2860 Q47864993 @default.
- Q60910566 P2860 Q50308754 @default.
- Q60910566 P2860 Q50857010 @default.
- Q60910566 P304 "885-894" @default.
- Q60910566 P31 Q13442814 @default.
- Q60910566 P356 "10.3892/OR.2018.6917" @default.
- Q60910566 P407 Q1860 @default.
- Q60910566 P433 "2" @default.
- Q60910566 P478 "41" @default.
- Q60910566 P577 "2019-02-01T00:00:00Z" @default.
- Q60910566 P698 "30535452" @default.
- Q60910566 P921 Q18553852 @default.
- Q60910566 P921 Q29496 @default.
- Q60910566 P932 "6312959" @default.